Acute insomnia: experience of treatment with doxylamine

Insomnia is a common clinical condition characterized by difficulty initiating and/or maintaining sleep. According to most epidemiological studies, about a third of adults (30–36%) report at least one symptom of insomnia, such as having difficulty falling asleep or maintaining sleep. Insomnia interferes with the full-fledged social and professional functioning of patients, forcing them to visit doctors more often, take sick leave. While therapeutic approaches are actively developed and discussed in chronic insomnia, acute insomnia due to the transient state and the tendency (in some cases) to spontaneous resolution often remains the subject of underdiagnosis and undrtreatment. Antihistamines that are non-addictive and have a narrower side-effect profile and are nonprescription drugs are an alternative in the pharmacological treatment of insomnia, especially secondary and transient insomnia, which is widespread in the population. Donormil (doxylamine succinate) is a blocker of H1-histamine receptors from the ethanolamine group. Donormil (doxylamine succinate) is a blocker of H1-histamine receptors from the ethanolamine group. Doxylamine is successfully used in both psychiatric and general medical practice, including dermatology, allergology, and gynecology.This article presents the clinical observation of a patient with acute insomnia arising in adjustment disorder and was accompanied by anxiety and mild conversion symptoms.. Donormil therapy during two weeks allowed to reduce acute insomnia: the time to fall asleep and the number of night awakenings decreased, cognitive impairment, distraction, and asthenia associated with insomnia reduced. No significant side effects were observed

Acute insomnia: experience of treatment with doxylamine

Insomnia is a common clinical condition characterized by difficulty initiating and/or maintaining sleep. According to most epidemiological studies, about a third of adults (30–36%) report at least one symptom of insomnia, such as having difficulty falling asleep or maintaining sleep. Insomnia interferes with the full-fledged social and professional functioning of patients, forcing them to visit doctors more often, take sick leave. While therapeutic approaches are actively developed and discussed in chronic insomnia, acute insomnia due to the transient state and the tendency (in some cases) to spontaneous resolution often remains the subject of underdiagnosis and undrtreatment. Antihistamines that are non-addictive and have a narrower side-effect profile and are nonprescription drugs are an alternative in the pharmacological treatment of insomnia, especially secondary and transient insomnia, which is widespread in the population. Donormil (doxylamine succinate) is a blocker of H1-histamine receptors from the ethanolamine group. Donormil (doxylamine succinate) is a blocker of H1-histamine receptors from the ethanolamine group. Doxylamine is successfully used in both psychiatric and general medical practice, including dermatology, allergology, and gynecology.This article presents the clinical observation of a patient with acute insomnia arising in adjustment disorder and was accompanied by anxiety and mild conversion symptoms.. Donormil therapy during two weeks allowed to reduce acute insomnia: the time to fall asleep and the number of night awakenings decreased, cognitive impairment, distraction, and asthenia associated with insomnia reduced. No significant side effects were observed.</jats:p

Personality and psychopathological profile of patients and botulinum therapy for blepharospasm

Background. Blepharospasm (BS) includes non-motor symptoms manifested by psychopathological disorders. The impact of these disorders on patients' quality of life and therapy of motor symptoms with botulinum toxin is poorly understood.&#x0D; Aim. To analyze the correlation of different characterological personality abnormalities (CPA) with the BS severity and the response to botulinum toxin therapy (BT).&#x0D; Materials and methods. Forty-six BS patients (29 females, 17 males) aged 30 to 85 years (6111.5) with BS were examined. The control group included 46 healthy individuals (39 females and 7 males, with a mean age of 56.49.67). Patients were examined before and after BT (after 12 months) using the BS severity scale (BSDI), EQ-5D (EQ-5D-3L) quality of life assessment scales, General Anxiety Disorder (GAD-7) scale, Brief Fear of Negative Evaluation Scale (BFNE-S), and SCID-II-PD structured personality questionnaire.&#x0D; Results. In the BS group of patients, unemployed and non-married were more common (p0.05) than in healthy individuals. In the BS patient group, there was an increase in anxiety (15.525.6 vs 4.283.5 control group by GAD-7 scale) and fear of negative evaluation (42.449.2 in the main group vs 21.347.3 in the control group). Quality of life was lower in BS patients (65.43, median 62 vs 88.2, median 92, p0.05). The prevalence of cluster C CPA (anxiety disorders) in patients with BS and, in particular, the obsessive-compulsive disorder was revealed. Patients with different personality profiles showed no differences in the BS severity before BT. The BT efficacy was higher in patients with cluster C CPA.&#x0D; Conclusion. BS patients often have anxious type CPA; in these patients, BT is more effective than in other CPAs.</jats:p

Personality Disorders and Traits of ABC Clusters in Fibromyalgia in a Neurological Setting

Background: Evidence suggests that there is substantial comorbidity between fibromyalgia and Axis II pathology (i.e., personality disorders&mdash;PDs). The aim of the current study was to find out the exact cluster (A, B, C) of PDs or traits that are more prominent in FM and may be predictors of FM diagnosis. Methods: Data from 86 subjects (53 with FM and 33 controls without FM) were analyzed in an observational, cross-sectional, comparative study in a neurological setting. The assessment of categorical PDs and traits was performed independently with the Structured Clinical Interview for Personality Disorders (SCID-II). Binary logistic regression was used to determine FM predictors among PD traits. Results: Compared with controls, FM patients had a higher rate of PD diagnoses (56.7 vs. 18.2%, p &lt; 0.001). However, the rate was significantly higher only for borderline PD diagnosis (28.3% vs. 6.1% p &lt; 0.05). The binary logistic regression analysis showed that schizotypal and schizoid (cluster A), borderline (cluster B), and dependent (cluster C) personality traits may be significant predictors of fibromyalgia (Nagelkerke R2 = 0.415). Conclusions: Our results may reflect the association of FM with personality traits of all three PD clusters: A (eccentric), B (dramatic), and C (anxious). However, the most consistent evidence seems to be for borderline PD

Eros, literature and the Veroli Casket

No description supplie

Scriptural citation in Andronikos Kamateros

La citazione biblica come strumento retorico